Analysts tip Inventiva's lanifibranor as NASH blockbuster

Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals i

Genfit’s NASH hopes are dashed by phase 3 trial fail

Genfit has seen almost two-thirds of the value wiped off its shares after its much-anticipated pivotal trial of non-alcoholic steatohepatitis (NASH) drug elafibranor turned out

BI buys rights to NASH-targeted tech from Singapore's Enleof...

Boehringer Ingelheim has bought rights to preclinical technology aimed at fibro-inflammatory diseases including the fatty liver disease known as NASH, a prime target for many pharma compani

NorthSea Therapeutics raises $40m to develop NASH drug

Dutch biotech NorthSea Therapeutics has raised around $40 million in a series B financing round to help it develop novel strategies to treat the fatty liver disease known as NASH.<

Forendo works with Novartis in liver disease, possibly targe...

Finland’s Forendo Pharma has signed a deal with Novartis aimed at identifying novel drugs for treatment of chronic liver diseases, with the potentially lucrative fatty liver disease known a

Another NASH setback as CymaBay drops seladelpar